Genome-derived vaccines

Abstract

Vaccine research entered a new era when the complete genome of a pathogenic bacterium was published in 1995. Since then, more than 97 bacterial pathogens have been sequenced and at least 110 additional projects are now in progress. Genome sequencing has also dramatically accelerated: high-throughput facilities can draft the sequence of an entire microbe (two to four megabases) in 1 to 2 days. Vaccine developers are using microarrays, immunoinformatics, proteomics and high-throughput immunology assays to reduce the truly unmanageable volume of information available in genome databases to a manageable size. Vaccines composed by novel antigens discovered from genome mining are already in clinical trials. Within 5 years we can expect to see a novel class of vaccines composed by genome-predicted, assembled and engineered T- and B-cell epitopes. This article addresses the convergence of three forces – microbial genome sequencing, computational immunology and new vaccine technologies – that are shifting genome mining for vaccines onto the forefront of immunology research.

• biopathogen
• CTL
• epitope
• genome
• genomics
• immunome
• proteome
• proteomics
• Thelpervaccine